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Background: Hypothyroidism is a frequent late side effect of radiation therapy of the cervical region. Purpose of
this work is to develop multivariate normal tissue complication probability (NTCP) models for radiation-induced
hypothyroidism (RHT) and to compare them with already existing NTCP models for RHT.
Methods: Fifty-three patients treated with sequential chemo-radiotherapy for Hodgkin’s lymphoma (HL) were
retrospectively reviewed for RHT events. Clinical information along with thyroid gland dose distribution parameters
were collected and their correlation to RHT was analyzed by Spearman’s rank correlation coefficient (Rs).
Multivariate logistic regression method using resampling methods (bootstrapping) was applied to select model
order and parameters for NTCP modeling. Model performance was evaluated through the area under the receiver
operating characteristic curve (AUC). Models were tested against external published data on RHT and compared
with other published NTCP models.
Results: If we express the thyroid volume exceeding X Gy as a percentage (Vx(%)), a two-variable NTCP model
including V30(%) and gender resulted to be the optimal predictive model for RHT (Rs = 0.615, p < 0.001. AUC = 0.87).
Conversely, if absolute thyroid volume exceeding X Gy (Vx(cc)) was analyzed, an NTCP model based on 3 variables
including V30(cc), thyroid gland volume and gender was selected as the most predictive model (Rs = 0.630,
p < 0.001. AUC = 0.85). The three-variable model performs better when tested on an external cohort characterized
by large inter-individuals variation in thyroid volumes (AUC = 0.914, 95% CI 0.760–0.984). A comparable performance
was found between our model and that proposed in the literature based on thyroid gland mean dose and volume
(p = 0.264).
Conclusions: The absolute volume of thyroid gland exceeding 30 Gy in combination with thyroid gland volume
and gender provide an NTCP model for RHT with improved prediction capability not only within our patient
population but also in an external cohort.
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Radiation-induced hypothyroidism (RHT) is a frequent
side effect after therapeutic irradiation of the cervical
region and it has been described in patients undergoing
radiation therapy (RT) for different neoplasms such as
lymphoma, head-and-neck cancer and breast cancer [1-3].* Correspondence: laura.cella@cnr.it
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reproduction in any medium, provided the orThe amelioration of life span expectations of cancer
patients requires the maximum possible effort to reduce
iatrogenic diseases like RHT. The evolution of radiation
therapy technology has enhanced the ability to adapt RT
techniques to the individual patient. However, in order
to establish tailored strategies for a risk-adapted RT, it is
essential to identify specific clinical and dosimetric
parameters that are involved in the process of modeling
normal tissue complication probability (NTCP). Input
parameters have been recognized to be among the most
critical features of an effective NTCP model [4]. Modelsd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Patient, disease and treatment characteristics
Median age (years) 27.5 (14–70)





Nodular sclerosis 38 71.7






30 Gy 23 43.4
32 Gy 25 47.2
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patient-related and dosimetric factors may offer a power-
ful approach to the optimization of risk ascertainment for
many different endpoints [5]. As a consequence, data-
driven multivariate modeling of NTCP [6] is increasingly
being used unlike traditional NTCP models that only
involve dose distribution parameters of a specific organ at
risk like the Lyman-Kutcher-Burman model.
Recently, a multivariate NTCP model for RHT based on
mean thyroid dose and thyroid volume was developed by
Boomsma et al [7] in patients treated for head-and-neck
cancer. A thyroid volume effect in RHT development,
following RT of breast cancer, was also emphasized in a
case-control study where the absolute volume receiving
more than 30 Gy was recognized as a critical factor for
hypothyroidism development [8]. In a previous work [9]
on RHT in Hodgkin’s lymphoma (HL) patients, after con-
ventional multivariate analysis method, the percentage of
thyroid volume exceeding 30 Gy (V30(%)) was found to be
the only predictor of RHT. All the above mentioned
results, although similar, are not coincident and seem to
suggest different prognostic variables for RHT among
patients from different populations.
In this framework, the present report expands on the
potential of building an effective multivariate NTCP
model for RHT and extends the complexity of the
analysis in order to evaluate if general information on
RHT risk assessment may be extrapolated regardless of
the cohort of patients on which the model is built on.
To this end, NTCP modelling exercises were performed
using bootstrapping together with validation and per-
formance comparisons on different patients cohorts
evaluated for RHT using data from the literature [7-9].
Methods
Patient dataset
Data on 61 consecutive patients with HL undergoing
post-chemotherapy supradiaphragmatic involved-field ra-
diation therapy at the Radiation Oncology Department of
the University “Federico II” of Naples were retrospectively
reviewed for RHT events. Selection criteria included the
patients informed consent, availability of thyroid hor-
mones serum data before chemotherapy, after chemother-
apy, and, periodically, after RT as well as the availability of
treatment planning data. Blood levels of thyroid stimulat-
ing hormone (TSH), free triiodo-thyronine (FT3), free
thyroxine (FT4), thyroglobulin antibody (ATG) were eval-
uated. The study was approved by the ethics committee of
our institution. A diagnosis of RHT (event) was based on
TSH value greater than the maximum value of laboratory
range and/or FT3 and/or FT4 values lower than the mini-
mum value of laboratory range, whether any symptom
was present or not (subclinical or clinical RHT). Eight
patients (13.1%) had hypothyroidism before treatment,and were consequently excluded from further evaluation.
General patient characteristics are given in Table 1.
Twenty-two out of 53 patients (41.5%) developed labora-
tory evidence of hypothyroidism at a median follow-up of
32 months (range 6–99) after the end of radiation
treatment [9].
All patients were treated with full 3D CT based
radiation treatment planning as described in detail in a
previous publication [10]. In short, three-dimensional
conformal plans were generated using a commercial treat-
ment planning system (XiO, Elekta CMS. St Louis. MO)
and the convolution dose calculation algorithm, appropri-
ate in the presence of heterogeneous tissues, was applied.
RT was administered using 6 -20 MV photon beams from
a linear accelerator with anteroposterior-posteroanterior
fields. A total median dose of 32 Gy (range 30–36) in 20
daily fractions of 1.5–1.8 Gy was planned. For all patients,
the thyroid gland was retrospectively delineated on pur-
pose on the planning CT-images by the same radiation
oncologist (M.C.). The thyroid gland volume, the mini-
mum (Dmin), maximum (Dmax) and mean doses (Dmean),
the absolute volume of thyroid and the percentage of
thyroid volume exceeding 10, 20 and 30 Gy (Vx(cc) and
Vx(%), respectively) were calculated from the dose volume
histograms. In addition, the “residual X Gy thyroid
volume”, defined as the difference between the thyroid
gland volume and Vx (cc), was calculated.
Statistical modeling
Dosimetric parameters of the thyroid gland along with
patient clinical information (thyroid gland volume, age,
Figure 1 The cross-correlation matrixes for the variables belonging to set 1 (a) and to set 2 (b). The colorbar represents the Spearman’s
rank correlation coefficient value. NTCP: normal tissue complication probability , Vx (%):percentage of thyroid volume exceeding X Gy; Vx (cc):
absolute thyroid volume exceeding X Gy.
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http://www.ro-journal.com/content/7/1/224gender, chemotherapy, and clinical stage) were included
in the analysis. Univariate logistic analysis for each vari-
able was performed using the Spearman’s rank correl-
ation (Rs) coefficient to assess inter-variable correlation
and correlation with RHT risk.
We separately analyzed two sets of candidate predictors:
set 1 includes the clinical variables, plus Dmin, Dmax, Dmean
and Vx(%), and set 2 includes the same variables as set 1
but Vx was expressed as absolute volume, Vx (cc).
To identify combinations of variables that were likely to
be most predictive of RHT, we used automated logistic
regression with bootstrap technique for variable selectionFigure 2 The five most frequently selected models by bootstrap sam
tissue complication probability , Vx (%): percentage of thyroid volume exceand bootstrap resampling to test selection stability [6].
The logistic regression model is defined as
NTCP ¼ 1
1 þ eg xð Þ ð1Þ
with
g xð Þ ¼ β0 þ β0x1 þ β1x1 þ . . . βnxn ð2Þ
Where x1, x2 . . .  xn represent different input variables
and β0, β1 . . .  βn are the corresponding regression
coefficients.pling technique: (a) variable set 1; (b) variable set 2. NTCP: normal
eding X Gy; Vx (cc): absolute thyroid volume exceeding X Gy.
Table 2 Best-fitted regression coefficients and 95%
confidence intervals for model 1 and model 2
Parameter Estimated coefficient StdError p-value
Model 1
gender −2.32 0.83 0.0062
V30(%) 0.038 0.01 0.0009
constant −1.83
Model 2
gender −2.21 0.85 0.0110
V30(cc) 0.26 0.09 0.0021
thyroid volume (cc) −0.27 0.11 0.0140
constant 1.94
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between two variables was greater than 0.85 we excluded
the one with the lowest correlation with RHT [11] from
the subsequent multivariate analysis.
Data analysis was performed by an open source avail-
able package (Dose Response Explorer System [12]) for
combined modeling of multiple dosimetric parameters
and clinical factors using multi-term regression modeling.
In summary, the modeling process consists of a two-step
process. In a first step, the model size (number of variables
significantly predictive) is estimated by bootstrapping and
in the second step regression coefficients are estimated
using forward selection on multiple bootstrap samples,
the most frequent model being the optimal one. Model
predictive power is quantified using Rs correlation
coefficient while the area under the receiver operating
characteristic curve (AUC) was used to evaluate the dis-
criminating ability of model fits.Figure 3 Model 2 NTCP surfaces for males and females as a functionSubsequently, the obtained NTCP models were vali-
dated against an independent external cohort. To this
end, data on RHT in breast cancer patients with irra-
diated supraclavicular lymph nodes were taken from the
literature [8]. For comparison purpose, we also evaluated
the NTCP model for RHT proposed by Boomsma et al
[7] that is based on thyroid gland mean dose and vol-
ume. Model comparison was performed using a z test
on the AUC of receiver operating characteristic (ROC)
curves. A p value less than 0.05 was considered statisti-




The cross-correlation matrixes for the variables belonging
to set 1 and set 2, respectively, are shown in Figure 1a-b.
For both set of variables, a strong multiple correlation
(i.e. Rs > 0.85) between dosimetric parameters was found.
After applying the selection criteria to avoid overfitting to
set 1, V30 (%) and Dmax resulted to be the dosimetric para-
meters that should be included in the multivariate analysis
along with clinical variables. Similarly, for set 2, V30 (cc),
Dmax e Dmean were selected along with clinical variables.
In set 1, a two-variable model was suggested as the
optimal order by bootstrap method. Figure 2a shows the
five most frequently selected models within the boot-
strapped subpopulations. The optimal model (Rs = 0.615,
p < 0.001) includes gender (female =0, male = 1) and V30
(%) (model 1). The best-fitted regression coefficients are
given in Table 2. According to this model, the risk of









of V30(cc) and thyroid volume (cc).
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suggested as the optimal order by bootstrap method.
Figure 2b shows the five most frequently selected mod-
els within the bootstrapped subpopulations. The optimal
model (Rs = 0.630, p < 0.001) includes gender, V30(cc)
and thyroid gland volume (model 2). The best-fitted re-
gression coefficients are given in Table 2. As for model
1, the risk of RHT increases as V30(cc) increases and it is
higher for female patients; in addition the risk decreases
with larger volume of thyroid gland. Model 2 NTCP sur-
faces for males and females are represented in Figure 3.
Actually, we can consider the above model 1 and model
2 as equivalent models being V30(%) the ratio of V30(cc) to
thyroid gland volume. In our previous work [9] we already
found that thyroid V30(%) predicts the risk of developing
RHT. However other groups [7,8] have shown a thyroid
gland volume effect in RHT development: the risk
increases with smaller thyroid gland volume. For this rea-
son, in this work we separately analyze the Vx parameters
as percentages and as absolute volumes.
It is interesting to note that both our NTCP models
include gender. This result is in agreement with the meta-
analysis by Vogelius et al [13] who identified gender,
together with race and surgery of the neck, to be as a sig-
nificant prognostic clinical variable in RHT development.
Models’ comparison and validation
The obtained models were then compared by using the
AUC (Table 3) of the ROC curves depicted in Figure 4a-b.
As expected, no difference in performance was found
between model 1 and model 2 (p = 0.76) for our cohort of
patients (Figure 4a).
Applying model 1 and model 2 to the external case-
control cohort of breast cancer patients, we have obtained
the ROC curves showed in Figure 4b. In this case, modelTable 3 Area under the receiver operating characteristic
curve (AUC) and 95% confidence intervals for all the
models applied on our Hodgkin’s lymphoma (HL) dataset
and on an external breast cancer dataset [8]
AUC 95% CI p value
HL dataset
Model 1 0.865 0.793–0.945
Model 2 0.874 0.750–0.951 0.760*
Boomsma model [7] 0.718 0.573–0.836 0.044*
0.023§
External dataset
Model 1 0.568 0.382–0.741
Model 2 0.914 0.760–0.984 0.005*
Boomsma model [7] 0.898 0.740–0.977 0.009*
0.264§
Significance level was obtained using z test.
* evaluated respect to model 1.
§ evaluated respect to model 2.1 fails to predict RHT (AUC= 0.568, 95% CI 0.328-0.741)
while model 2 has a high performance (AUC = 0.914,
95% CI 0.768–0.984). This result can be ascribed to the
fact that, unlike our patients, the external cohort is cha-
racterized by large inter-individual and inter-group varia-
tions in thyroid volumes. Therefore model 2, where V30 is
expressed as absolute volume coupled with the thyroid vol-
ume, results to be more effective in RHT prediction.
Subsequently, we have analyzed the Boomsma NTCP
model for RHT. It should be noted that these authors
reported an AUC of 0.85 (95% CI 0.78–0.92) on their
head-and-neck cancer patient dataset. The Boomsma
model and model 1 and model 2 performances are not
statistically different (p = 0.67) when each is evaluated
on its own internal data set.
The ROC curves generated applying the Boomsma
model on our HL dataset and on the breast cancer data-
set are shown in Figure 4a and 4b, respectively.
On our cohort of patients, the performance of
Boomsma NTCP model resulted statistically lower than
that of model 1 or model 2 (p < 0.05). Conversely, on
validation breast cancer cohort model 2 and Boomsma
model have comparably high performance (p = 0.26).
Based on the AUC analysis, both model 2 and Boomsma
model seem to be successfully applicable to predict RHT
also on a different population.
The difference between the above models relies on the
use of V30 (cc) and gender for model 2 and on the use of
Dmean for Boomsma model, while the thyroid gland
volume is a common variable. The different selection of
dosimetric variables may be ascribed to the relatively high
uniform thyroid dose distribution in a head-and-neck
cancer cohort (where up to 70 Gy are prescribed with a
V30(cc) probably equal to the thyroid gland volume)
compared with thyroid dose distribution in our Hodgkin
lymphoma patients treated with a median dose of 32
Gy [14].
Besides the prediction performance, we believe that a
model that also considers gender could be advantageous
being the estimated rate of hypothyroidism in the gen-
eral population higher in women than in men [15]. In
addition, to explain higher susceptibility of women to
RHT, it has been assumed that RT could work as a
multiplicative factor that increases the baseline risk of
the general population [13]. This could justify the com-
parable performance of model 2 and Boomsma model
when applied on a uniform female cohort as the breast
cancer patient dataset, while a lower performance of
Boomsam model is observed when it is applied on HL
patients where female and male are almost homoge-
nously represented.
In treatment planning optimization procedures, the
separate use of thyroid gland volume along with a dosi-
metric parameter (V30(cc) or Dmean) is not easily tunable.
Figure 4 ROC curves for model 1, model 2, and Boomsma model [7]: (a) on Hodgkin’s lymphoma dataset (b) on external breast cancer
dataset [8].
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defined as the difference between the thyroid gland vol-
ume and V30(cc) may be easier to use. From our HL
data, the “residual 30 Gy thyroid volume” was found to
be a significant predictor of RHT as well (Rs = 0.56). The
median “residual 30 Gy thyroid volume” of patients with
RHT was 0.2 cc (range 0.0-15.6 cc) in contrast to a me-
dian value of 9.4 cc (range 0.0-31.2 cc) for those without
RHT. From ROC analyses we have estimated a cutoff
volume equal to 7 cc (AUC = 0.81, 95% CI 0.720-0.904)
for the “residual 30 Gy thyroid volume” as a critical
value above which there is a high probability for the
thyroid to maintain its functionality. This result is in
agreement with the work by Johansen et al [8] where a
median residual 30 Gy thyroid volume of 5 cc was found
in patients who developed RHT in contrast to a median
value of 11 cc in patients who did not develop RHT.
Conclusions
In this study we have developed a multivariate NTCP
model for RHT based on dosimetric and clinical variables:
the absolute volume of thyroid gland exceeding 30 Gy,
thyroid gland volume and gender. This three-variable
model provides an improved prediction capability not only
within our patient population but also in an external valid-
ation cohort. In addition, we have found a cutoff “residual
30 Gy volume” for thyroid gland that should be consid-
ered in the treatment planning procedure in order to
maintain the gland functionality.
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